Close

Kura Oncology (KURA) Presents Data from HRAS Mutant Solid Tumors Phase 2 Trial at ESOC-9

Go back to Kura Oncology (KURA) Presents Data from HRAS Mutant Solid Tumors Phase 2 Trial at ESOC-9

Kura Oncology Presents Update on Pipeline Programs Targeting RAS-ERK Pathway at European Scientific Oncology Conference

November 4, 2016 7:30 AM EDT

LA JOLLA, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical stage biopharmaceutical company, today presented preclinical findings and data from the companys ongoing Phase 2 trial in HRAS mutant solid tumors at the 9th European Scientific Oncology Conference (ESOC-9) in Marbella, Spain. Antonio Gualberto, M.D., Ph.D., chief medical officer, delivered a presentation titled, Targeting the RAS-ERK Pathway.

Kura is currently evaluating tipifarnib, a farnesyl transferase inhibitor, as a potential treatment for patients with HRAS mutant solid tumors. In his presentation, Dr. Gualberto provided details on... More